![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Imara Agrees to Sell Tovinontrine to Cardurion
Imara Agrees to Sell Tovinontrine to Cardurion
September 12, 2022
Imara has agreed to sell to Cardurion Pharmaceuticals its phosphodiesterase (PDE9) inhibitor tovinontrine (IMR-687) and all other assets related to its PDE9 program.
The decision follows Imara’s disappointing results from two clinical trials of tovinontrine in patients with beta thalassemia, a blood disorder that reduces the production of hemoglobin.
The drug failed to show meaningful improvements in the endpoints of total hemoglobin, transfusion burden, vaso-occlusive crises and fetal hemoglobin response.
The aggregate purchase price for Imara’s PDE9 assets includes an upfront cash payment of about $34.7 million, plus possible future payments of up to $60 million if certain milestones are achieved.
Upcoming Events
-
21Oct